Patrice Morand

Patrice Morand

Auto-generated profile, based on publicly available information

Patrice Morand

Laboratoire de Virologie, IBP, CHU Grenoble Alpes

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Scandinavian Journal of Infectious Diseases
Verified
Journal Article
Closed access
NRNathalie Roch
Nathalie Roch
DSDimitri Salameire
Dimitri Salameire
RGRemy Gressin
Remy Gressin
PMPatrice Morand
Patrice Morand
Olivier EPAULARDOlivier EPAULARD
Olivier EPAULARD
Jean-Paul StahlJean-Paul Stahl
Jean-Paul Stahl
Alemtuzumab is an antibody binding to CD52, an antigen expressed on lymphocytes. This immunotherapy has been tested as potential therapy in haematological malignancies. We report adenoviral and enteroviral infections and an EBV positive B-cell lymphoma after alemtuzumab therapy. These fatal opportunistic complications have been rarely, if ever, reported before.

1 October 2022 in Journal of Medical Virology
Verified
Journal Article
Open access
JLJulien Lupo
Julien Lupo
MTMansour Tsougaev
Mansour Tsougaev
SBStéphane Blachier
Stéphane Blachier
GCGuillaume Chovelon
Guillaume Chovelon
ATAurélie TRUFFOT
Aurélie TRUFFOT
PMPatrice Morand
Patrice Morand
Serological markers for Epstein–Barr virus (EBV) infection are commonly used to diagnose infectious mononucleosis and establish a serological status in pretransplant patients. This study prospectively assessed 1043 serum specimens sent to the laboratory for physician‐ordered EBV testing. The three markers—antiviral capsid antigen (VCA) immunoglobulin M (IgM), anti‐VCA immunoglobulin G (IgG), and anti‐Epstein–Barr nuclear antigen (EBNA) antibodies—were tested using the Elecsys and the Liaison immunoassays. Specimens with discrepant results between the two assays were assessed using further EBV diagnostic approaches to conclude on the EBV serological status. In spite of substantial agreement between the two assays (88%) and with the presumed EBV status (>92%), the results showed differences in the performance of the assays. Liaison VCA IgM appeared to be the most sensitive test for the detection of the 38 sera classified as early primary infection in comparison with the Elecsys assay (91.4% vs. 68.6%, p = 0.008). Excluding the cases of early primary infection, the sensitivity values of the VCA IgM marker were comparable between the Liaison and Elecsys assays (95.2% and 92.9%, respectively, p = 1). Concerning the sera classified as past infection ( n = 763), the Elecsys assay showed higher sensitivity values for the detection of the VCA and EBNA IgG markers in comparison with the Liaison assay (99.9% and 99.7% vs. 97.4% and 91.2%, respectively, p < 0.001). Overall, the Elecsys and Liaison assays showed similar performance. The interpretation of EBV serological profiles based on the clinical context may require serology follow up or further diagnostic approaches in challenging cases.


1 October 2017 in Journal of Clinical Virology
Verified
Journal Article
Closed access
Olivier EPAULARDOlivier EPAULARD
Olivier EPAULARD
ASAnne Signori-Schmuck
Anne Signori-Schmuck
SLSylvie Larrat
Sylvie Larrat
OKOm Kulkarni
Om Kulkarni
MBMichael G. Blum
Michael G. Blum
PMPatrice Morand
Patrice Morand

2 June 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
MUMarie Usal
Marie Usal
JAjulien Andreani
julien Andreani
ATAurélie TRUFFOT
Aurélie TRUFFOT
CCCapucine Chevalier
Capucine Chevalier
SLSylvie Larrat
Sylvie Larrat
RGRaphaële Grenoble-Alpes
Raphaële Grenoble-Alpes
This study compared the analytical performance of three commercial real-time PCR assays for the detection of monkeypox virus (MPV) DNA, on their own platforms and/or on open platforms, were evaluated at the virology laboratory of Grenoble-Alpes University Hospital (CHUGA): the VIASURE monkeypox virus real-time PCR Reagents on the BD MAX System; the MPXV AMP Kit on the Alinity m system; and the Altona RealStar Zoonotic Orthopoxvirus PCR Kit 1.0 on the Argene System (EMAG, ESTREAM [Biomérieux], and LC480 [Roche]). Results obtained on these platforms were compared to those from the French National Reference Center (NRC) for orthopoxviruses. A total of 52 samples were selected by the NRC and the CHUGA: 8 dilutions of MPV culture supernatant, 2 supernatants from cowpox and vaccinia virus cultures, 32 clinical samples (20 positive/12 negative), and 10 external quality control samples from the “Quality Control for Molecular Diagnostics” (QCMD) program. The sensitivity and specificity of the three assays, compared to the NRC assay, were 100% on the samples tested. All positive samples were correctly identified as positive with all three assays, and all negative samples were negative for MPV detection. Overall, the cycle threshold (Ct) values obtained with the VIASURE, Abbott, and Altona assays were lower than those obtained with the NRC PCR in 84.38%, 81.25%, and 75.86% of positive samples, respectively. In conclusion, all three assays demonstrated good analytical performance and were suitable for MPV detection. IMPORTANCE: Mpox is an emerging zoonotic disease caused by the monkeypox virus, mostly reported in Africa. In 2022, an outbreak characterized mainly by anogenital rash in MSM (men having sex with men) occurred in Europe. In 2024, many cases of infection were reported, presenting with generalized skin rashes. Detection of monkeypox virus DNA in biological samples is crucial for diagnosis, interruption of transmission chains, treatment initiation, and vaccination. During the European outbreak in 2022, numerous companies rapidly developed qPCR kits. In France, the performance of these kits has been evaluated by the French National Reference Center (NRC) for orthopoxviruses. The Grenoble-Alpes University Hospital collaborated with the NRC to evaluate three available assays on its own platforms and/or on open platforms available in its virology laboratory. All three assays demonstrated good analytical performance and can be used with confidence.